| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10966497 | Vaccine | 2014 | 6 Pages |
Abstract
In this safety surveillance study of more than 200,000 DTaP-IPV vaccine recipients, there was no evidence of increased risk for any of the pre-specified adverse events monitored. Continued surveillance of DTaP-IPV vaccine safety may be warranted to monitor for rare adverse events, such as Guillain-Barré syndrome.
Keywords
Diphtheria, tetanus, and acellular pertussis vaccineMMRVICD-9-CMMMRDTaPVSDIPVImmunizationVaccine safetyVaccine Safety Datalinkemergency departmentACIPDiphtheriaInternational Classification of Diseases, 9th revision, Clinical ModificationtetanusSurveillanceVaccineMeasles–mumps–rubella vaccineInactivated poliovirus vaccineAdvisory Committee on Immunization Practicesacellular pertussis
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Matthew F. Daley, W. Katherine Yih, Jason M. Glanz, Simon J. Hambidge, Komal J. Narwaney, Ruihua Yin, Lingling Li, Jennifer C. Nelson, James D. Nordin, Nicola P. Klein, Steven J. Jacobsen, Eric Weintraub,